Figure 3 | Scientific Reports

Figure 3

From: HA1077 displays synergistic activity with daclatasvir against hepatitis C virus and suppresses the emergence of NS5A resistance-associated substitutions in mice

Figure 3

Antiviral efficacy of combination of HA1077 and HCV direct-acting antiviral agents (DAAs). (a) Huh7-derived R-1 cells harboring a GT1b HCV subgenomic replicon was treated with HA1077 (20 μM) and indicated HCV DAAs (EC90 of each compound). Two days after drug treatment, intracellular HCV load was determined by RT-qPCR. Data are mean ± s.d. from of three independent experiments, each involving triplicates. (b) Synergy effect of combination of daclatasvir (DCV) and HA1077 was assessed by calculating the combination index (CI) values for a representative experiment. CI < 1, synergism; CI = 1, additive effect; and CI > 1, antagonism. (c,d) Suppression of DAA-resistant mutant generation by combining HA1077 with DCV. R-1 cells were cultivated in the presence of G418 (0.5 mg/ml) and the indicated combinations of HA1077 and DCV for 5 weeks to select for DCV resistant mutants (c). Quantification of drug-resistant colonies using the ImageJ program (d). **P < 0.01 by unpaired two-tailed Student’s t-test.

Back to article page